Boston Scientific has lowered its 2026 expectations, now calling for organic revenue growth of 5% to 6% and adjusted earnings per share of $3.28 to $3.32, or 7% to 8% growth, as weakness in its WATCHMAN and Electrophysiology businesses weighs on performance. Management expects the pressure to extend into 2027, with revenue growth potentially remaining below its weighted average market growth rate and adjusted EPS growth limited. However, growth could pick up meaningfully in 2028, driven by seven new launches that collectively address a total addressable market of nearly $25 billion, including the SEISMIQ 4CE Coronary IVL Catheter and the FARAWAVE Ultra mapping and ablation catheter, as well as the pending Penumbra acquisition. The company is also pursuing a restructuring program targeting approximately $500 million in annual run-rate savings by the end of 2029, with more than half expected by the end of 2027, to support operating-margin expansion and stronger adjusted EPS growth in 2028 and beyond.
Boston Scientific CorpWeakness in WATCHMAN and Electrophysiology businesses lowers 2026 outlook
Penumbra IncPending acquisition by Boston Scientific mentioned as part of growth strategy
Abbott Laboratories
Globus Medical